ICU
SeaStar Medical Sets Sights on Expanding Treatment Options for Critical Conditions
SeaStar Medical, a leading biotechnology company focused on developing innovative treatments for ultra-rare and critical conditions, has announced its impressive achievements in the fourth quarter of 2025. In a recent conference call, Eric Schlorff, Chief Executive Officer, highlighted the company's progress in expanding the use of QUELIMMUNE therapy